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Abstract  
Background: The high societal burden of schizophrenia is largely caused by the 
persistence of symptoms and accompanying functional impairment. To date, no studies have 
specifically assessed the course of persistent symptoms or the individual contributions of 
positive and negative symptoms to patient functioning. The cross-sectional analysis of the 
Pattern study provides an international perspective of the burden of schizophrenia. 
 
Methods: Clinically stable outpatients from 140 study centers across eight countries 
(Argentina, Brazil, Canada, France, Germany, Italy, Spain and the United Kingdom) were 
assessed using clinical rating scales: Positive and Negative Syndrome Scale (PANSS), 
Clinical Global Impression-Schizophrenia (CGI-SCH) Scale and the Personal and Social 
Performance (PSP) Scale. Additional measures included patient-reported outcomes, patient 
socio-demographic variables, living situation, employment and resource use. 
 
Results:  Overall, 1379 patients were assessed and analyzed and had similar 
sociodemographic characteristics across countries, with 61.6% having persistent positive 
and/or negative symptoms. Positive and negative symptoms had been persistent for a mean 
of 9.6 and 8.9 years (SD: 8.8 and 9.6), respectively. Approximately 86% of patients had a 
functional disability classified as greater than mild. Patients with a higher PANSS Negative 
Symptom Factor Score were more likely to have a poorer level of functioning. 
 
Conclusions: This analysis examines individual contributions of persistent positive and 
negative symptoms on patient functioning in different countries. A high prevalence of 
patients with persistent symptoms and functional impairment was a consistent finding across 
countries. Longitudinal observations are necessary to assess how to improve persistent 
symptoms of schizophrenia and overall patient functioning. 
 
ClinicalTrials.gov Identifier: NCT01634542.  
 
Keywords: Schizophrenia, persistent negative symptoms, persistent positive symptoms, 
epidemiology, quality of life, functional impairment 
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1. Introduction 
Schizophrenia is a severe mental disorder associated with high personal, family and societal 
burden (Van Os and Kapur, 2009). It is characterized by the presence of a variety of 
symptoms, which are commonly divided into three main symptom domains: 1) psychotic 
symptoms such as delusions, hallucinations (reality distortion) and disorganization (thought 
disorders and bizarre behavior); 2) negative symptoms, which include affective flattening, 
paucity of thought or speech, lack of motivation and emotional and social withdrawal; and 3) 
cognitive impairment (especially in memory, attention and executive function) (Liddle, 1987; 
Malla et al., 1993). The annual incidence of schizophrenia averages 15 per 100,000 and the 
lifetime prevalence is approximately 1% (Tandon et al., 2008). Schizophrenia is one of the 
most costly mental disorders in terms of human suffering and societal expenditure. This high 
burden to patients, their families and wider society is predominantly caused by the 
persistence of symptoms and occurrence of relapse throughout the course of illness. 
 
A substantial proportion of patients with schizophrenia experience residual and unremitting 
positive symptoms despite antipsychotic treatment (Suzuki et al., 2012; Suzuki et al., 2011). 
Approximately 70% of patients treated with antipsychotics show improvement in positive 
symptoms in the short-term (up to 6 months). However, the response is not consistent or 
fully effective for all patients (Menezes et al., 2006; Novick et al., 2007; Novick et al., 2009; 
Van Os and Kapur, 2009).  Indeed, it has been estimated that around two-thirds of patients 
continue to experience significant symptoms two years after treatment initiation, and 
approximately one-third will continue to experience these symptoms six years after diagnosis 
(Hegarty et al., 1994; Menezes et al., 2006; Novick et al., 2007; Novick et al., 2009). 
Insufficiently controlled positive symptoms can lead to poor patient outcomes, including 
relapse, rehospitalisation, impaired functioning and a reduced quality of life (Norman et al., 
1999; Norman et al., 2001; Novick et al., 2009; Csernansky and Schuchart, 2002; Doering et 
al., 1998; Postrado and Lehman, 1995; Menezes et al., 2006; Novick et al., 2007; Novick et 
al., 2009; Jordan et al., 2014).  
 
A recent follow-up study of individuals experiencing a first psychotic episode has challenged 
this negative prognosis. The AESOP-10 study followed up a cohort of 557 people with a first 
psychotic episode. Of the 126 patients with schizophrenia who were reevaluated about half 
of them were classified as having a good end state (Morgan et al., 2014). Seventy percent of 
the cases who were followed up had experienced at least a period of sustained remission. 
However, these results are somehow in conflict with recent review that found that the 
proportion of those with schizophrenia who recover on both symptom and functional 
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outcome is modest (approximately 14%). The discrepancies can be explained by disparities 
in the patient samples, whether first-episode or not, but also by the lack of consistent 
definitions of remission and recovery. Recovery should be conceptualized as a multifaceted 
process, in which symptoms, functioning and patient perception need to be taken into 
account (McGrath et al., 2014). Recovery obviously depends on remission. Nevertheless, 
there are a number of other intervening factors affecting recovery that are responsible for the 
marked variation in outcome observed (Menendez-Miranda et al., 2015; Jordan et al., 2014). 
 
At any point in time, including during the first episode of illness, negative symptoms affect up 
to 60% of patients with schizophrenia (Bobes et al., 2010), with 30% having primary negative 
symptoms (Buchanan, 2007; Stahl and Buckley, 2007). Currently available antipsychotics 
may not have a direct effect on primary negative symptoms (Erhart et al., 2006); therefore, 
many patients experience persistent negative symptoms even after control of their positive 
symptoms (Stahl and Grady, 2004; Chue and Lalonde, 2014). The severity of negative 
symptoms is a predictor of poor patient functioning, also contributing, to a greater extent 
than positive symptoms, to worse patient outcomes (Fervaha et al., 2014 (a); Fervaha et al., 
2014 (b)). Negative symptoms affect the ability of the patient to live independently, perform 
activities of daily living, engage in social activity, maintain personal relationships and 
participate in work or study (Rabinowitz et al., 2012; White et al., 2009; Novick et al., 2009). 
This impact is often evident even within one to two years following treatment of a first 
episode of illness (Cassidy et al., 2010; Jordan et al., 2014). 
 
Resolution of persistent symptoms is necessary to achieve complete remission and serves 
to expand patient progress beyond just “stability” and towards improved social and 
occupational functioning. Furthermore, psychosocial therapies and rehabilitation are most 
effective when both positive and negative symptoms are effectively controlled (Andreasen et 
al., 2005). Many patients experience persistent morbidity over the course of their illness and 
the attainment of remission (defined as a ‘mild or less’ symptom level for the eight core 
Positive and Negative Syndrome Scale [PANSS] symptoms for at least six consecutive 
months) remains a significant challenge (Andreasen et al., 2005). A recent literature review 
of remission in schizophrenia reported that only 45–70% of first-episode and multi-episode 
patients fulfilled remission criteria at some point during treatment (Lambert et al., 2010).  
 
A number of epidemiological cohort studies have been followed but none has specifically 
evaluated the natural course of persistent positive and negative symptoms of schizophrenia 
or compared them between countries (Buchanan, 2007; Chakos et al, 2006; Haro et al., 
2003 (a); Haro et al., 2003 (b)). The Pattern study was designed to evaluate the burden and 
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course of schizophrenia, patient-reported outcomes, healthcare resource utilization and 
associated costs for patients with persistent symptoms of schizophrenia, not conditioned by 
any particular therapy or intervention, under standard routine clinical practice. In addition, 
family members and other informal carers were assessed for their burden and associated 
costs with caring for these patients. This study is unique in the field of schizophrenia owing 
to its analysis of the individual contributions of positive and negative persistent symptoms on 
patient functioning across countries. Whereas previous studies have evaluated the course of 
illness in patients with schizophrenia by assessing overall symptom burden, the Pattern 
study examines individual symptom subgroups. The study consists of two phases: a cross-
sectional assessment, which forms the baseline observation; and a longitudinal assessment, 
in order to collect data on all patients who were not in recovery at baseline. The aim of this 
study is to describe the characteristics of the patients with schizophrenia receiving outpatient 
treatment in different countries and to examine the relationship between the persistence of 
different types of symptoms and patient functioning. 
 
2. Materials and methods 
2.1 Study design 
Pattern is an international, multicenter, non-interventional, prospective, cohort study of 
schizophrenia patients attending psychiatric outpatient clinics. The study was conducted by 
psychiatrists treating patients with schizophrenia in outpatient facilities. Recruitment within 
the sites was based on a sequential selection from patients with a diagnosis of 
schizophrenia. From a list of current clinic patients generated for each site, those patients 
without a recent acute relapse, within the last three months according to the treating 
psychiatrist, were deemed eligible and invited to participate in the study. Patient care and 
treatment followed routine local clinical practice and was at the discretion of the treating 
clinician. In addition, family members and other informal carers were invited to participate in 
the study and were assessed for their burden and associated costs with caring for these 
patients. The protocol and consent procedures were approved by all local Institute Review 
Boards/Ethics Committees before study initiation.  
 
2.2 Participants 
Adult schizophrenia patients who were treated at psychiatric outpatient clinics were eligible 
for study entry. To maximize generalizability of study results to the whole population of 
clinically stable schizophrenia patients, minimal entry criteria were applied regardless of 
treatment history, comorbidity or history of substance abuse. Participants were at least 18 
years old and met criteria for schizophrenia according to the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition, Text Revision or International Classification of 
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Diseases, 10th Revision, documented with an abridged version of the Mini International 
Neuropsychiatric Inventory, of ≥ 12 months duration before the baseline observation. Family 
members and other informal carers were invited to participate in the study and respond to 
questionnaires. All patients and available family members and other informal carers were 
required to demonstrate ability and willingness to comply with the study protocol and provide 
informed consent. Exclusion criteria included: an acute psychotic exacerbation in the three 
months prior to baseline (e.g., hospitalization or increased psychiatric care in order to avoid 
hospitalization), enrolment in an interventional study at baseline and an inability or 
unwillingness to comply with the study protocol.  
 
2.3 Patient assessment 
Psychiatrists or appropriately trained professionals, patients and their family members or 
informal carers utilized an electronic hand-held tablet to capture all clinical assessment and 
patient-reported outcome (PRO) data. Psychiatrists captured data as assessed by clinical 
rating scales, whilst patients captured PRO questionnaire data independently at the clinic. 
To ensure instrument validity, PRO questionnaires were administered prior to the completion 
of other study assessments. At each outpatient attendance, approximately every 3 months 
for a year, patients were assessed using several clinical rating scales, which included: 
Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression-Schizophrenia 
(CGI-SCH) Scale and the PSP Scale. Participating psychiatrists were provided with training 
in the use of the questionnaires and rating was not blinded since no defined intervention was 
evaluated. PRO data were assessed by patients using the Schizophrenia Quality of Life 
Scale (SQLS) at each observation, the Short Form-36 (SF-36) at baseline and at one year 
and the EuroQol-5 Dimension (EQ-5D) questionnaire at approximately six month intervals 
(Table 1). Information on patient socio-demographics, living situation, employment, health 
service use and medical resource use was collected at each visit using the Client 
Socioeconomic and Services Receipt Inventory (CCSRI). Additional assessment tools 
included the caregiver’s Clinical Global Impression of change (CGI-Caregiver) and the 
Schizophrenia Caregiver Questionnaire (SCQ). In all cases, the available validated 
translated instruments were used. Whilst there is currently no consensus as to the 
operational criteria and definition of recovery in schizophrenia, previous literature has 
indicated that measures should be multidimensional and include clinical remission 
(maintained over a 6-month period) and social outcomes (Emsley, 2011; Andreasen, 2005). 
As such, recovery was defined per-protocol as PANSS Positive Symptom Factor Score <28, 
PANSS Negative Symptom Factor Score <20 and Personal and Social Performance (PSP) 
score ≥80 for at least the previous 6 months. 
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2.4 Statistical analysis  
The primary population for the present analysis, the Cross-Sectional Patient Analysis Set 
(CS-PAS), consists of all patients who fulfilled all the eligibility criteria for the cross-sectional 
phase, which included patients with persistent symptoms, those in symptomatic remission or 
those in recovery but not those with a psychotic exacerbation in the last three months. 
Psychotic exacerbation was defined as hospitalisation for schizophrenia-related reasons or 
increased psychiatric care in order to avoid hospitalisation, as judged by the psychiatrist. 
Descriptive statistics are provided for all variables of interest. Selected data are presented by 
country or according to the time since first treatment for schizophrenia (≤ 5 years and > 5 
years). Based on the ratings of the positive and negative dimensions of the PANSS and the 
PSP scales, patients were classified into the following non-overlapping symptom groups: 
predominantly negative persistent symptoms; sub-optimally controlled positive persistent 
symptoms; and symptomatic remission with poor level of functioning and recovery. 
Predominantly negative persistent symptoms was defined as a PANSS negative symptoms 
factor score (NSFS)>20 and PANSS positive symptoms factor score (PSFS)<28; sub-
optimally controlled positive persistent symptoms was defined as a PANSS PSFS >28 
(irrespective of PANSS NSFS score); symptomatic remission with poor level of functioning 
corresponded with PANSS PSFS ≤28, PANSS NSFS ≤20 and PSP <80; and recovery, as 
stated above, was characterized as PANSS PSFS <28, PANSS NSFS <20 and PSP ≥80 for 
at least the previous 6 months. The PANSS NSFS consists of seven PANSS items: Five 
‘negative symptoms’ (blunted affect, emotional withdrawal, poor rapport, passive-apathetic 
social withdrawal and lack of spontaneity and flow of conversation) and two ‘general 
psychopathology’ items (motor retardation and active social avoidance). The PANSS PSFS 
consists of eight PANSS items: Five ‘positive symptoms’ (delusions, hallucinatory behaviour, 
grandiosity, suspiciousness and stereotyped thinking) and three ‘general psychopathology’ 
items (somatic concern, unusual thought content and lack of judgement and insight) (Marder 
and Davis, 1997). 
 
Confidence intervals for the estimated multinomial proportions were calculated according to 
a method proposed by Sison and Glaz (Sison and Glaz, 1995). The relationships between 
numeric variables, such as the PSP total score and the PANSS NSFS, were assessed 
based on Spearman’s rank correlation analysis. The Kruskal–Wallis test was used to assess 
the relationship between PANSS score and the PSP-based function category. Analysis of 
covariance was used to assess the relationship of PSP with additional variables including 
the duration of illness and the country. The sample size of this study was based upon 
feasibility considerations.  
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3. Results 
 
3.1 Patient characteristics 
A total of 1433 patients were recruited into the Pattern study, from 140 study sites in eight 
countries (Argentina, Brazil, Canada, France, Germany, Italy, Spain and the United 
Kingdom). Overall, 1379 patients were included in the CS-PAS; 54 (3.8%) patients were 
excluded, the majority because they did not have a diagnosis of schizophrenia (primarily 
schizoaffective disorders). Socio-demographic information was similar across the eight 
countries (Table 2). Overall, patients were predominantly male (71%), with an average age 
of 42.1 years (standard deviation [SD]: 11.5; range: 18–82). Most patients were either single 
or unmarried (76.9%) and 27.2% had an informal carer. With regards to employment, only 
11.7% of patients were employed; 5.7% reported being in sheltered employment and 2.2% 
in voluntary/unpaid employment. The most frequent co-morbidities reported by clinicians 
were: current or past substance abuse (35%); another mental disorder (14%); vascular 
disease (7.8%); gastrointestinal disorders (7.5%); and metabolic disorders (7.5%).  
 
3.2 Persistence of symptoms 
The majority of patients (n=823, 61.6%) had either predominant sub-optimally controlled 
positive symptoms (PANSS Positive Symptom Factor Score>28) or predominant persistent 
negative symptoms (PANSS Negative Symptom Factor Score>20), the latter being the most 
common overall disease state (n=541, 40.5% of patients). The rest of the patients were in 
symptomatic remission with poor level of functioning (n=469, 35.1%) or recovery (n=43 
3.2%). The mean duration of persistent positive and negative symptoms, regardless of level 
of severity, was 9.6 (SD: 8.8) and 8.9 (SD 9.6) years, respectively, as reported by the study 
psychiatrist. In the previous year, 21% of patients were identified as being treatment 
resistant by their psychiatrist. Antipsychotics were used by 98% of patients and 31% of 
patients were on combination regimens (54% if drugs from other classes used for the same 
indication are considered, such as benzodiazepines or antidepressants). Clozapine was the 
most frequently prescribed antipsychotic (29% of patients, with figures ranging from 16% in 
France to 72% in Brazil) followed by risperidone (22%), olanzapine (16%) and aripiprazole 
(15%). 
 
 
3.3 Severity of disease  
Based on clinical ratings scales, most patients were experiencing moderately severe illness 
(Table 3). More than 86% of patients experienced a degree of functional disability classified 
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as greater than mild on the PSP scale (13% classified as patient requiring intensive support 
and supervision and 74% varying degree of disability), with only 13% of the patients 
experiencing mild difficulties. The duration of illness did not influence the level of functioning 
substantially. Patients with a higher PANSS NSFS were more likely to have worse level of 
functioning, as assessed by the PSP scale. A relationship with the PANSS PSFS was 
present but less pronounced. These effects were consistent across countries (Figures 1a/b).  
 
4. Discussion  
The cross-national characteristics of the Pattern study allowed comparison of various patient 
characteristics and outcome variables between countries, similar to recent investigations into 
psychopathological characteristics of patients with schizophrenia from Brazil, China and the 
US (Stefanovics et al., 2014). The data of more than 1300 patients and their family members 
or informal carers represent a valuable epidemiological contribution towards the study of 
schizophrenia. Clinically stable patients with a diverse range and severity of symptoms of 
schizophrenia were observed, and the majority of these patients (61.6%) were identified as 
having persistent positive and/or negative symptoms. This is consistent with previous studies 
in schizophrenia, which show that persistent symptoms are prevalent during the course of 
illness (Buchanan, 2007; Caspi et al., 2004; Hegarty et al., 1994; Menezes et al., 2006; 
Novick et al., 2007; Novick et al., 2009; Robinson et al., 2004; Van Os and Kapur, 2009).  
 
The patient characteristics observed here are similar to those observed in other outpatient 
studies of schizophrenia (Smith et al., 2006; Haro et al., 2003 (a)). Approximately, two thirds 
of the patients were male and mean age was around 42 years. Relevant differences 
appeared when comparing the living conditions across countries: in Canada, France, 
German and the UK  a low proportion of patients were living with their parents and other 
members of their family of origin, while in  Brazil, Italy and Spain the figures were two or 
three times higher. Cultural differences are probably underlying these differences (Sartorius 
et al., 1986; Brekke and Barrio, 1997). In these later countries the roles of families instead of 
formal services is much more important in taking care of patients with schizophrenia 
(Magliano et al., 2000). 
 
The level of impairment is very high, with twelve percent of patients having paid employment 
and ten percent of the patients being married. Previous research assessing patient 
functioning has generally focused on most developed countries (Marwaha et al., 2007, 
Marwaha and Johnson, 2004). Here we observe regional variations using a similar 
methodology. Canada, Germany and Italy have higher frequency of employment.  
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Employment policies for people with disabilities across countries may explain these 
differences. 
 
Notably, Pattern is one of the largest cohort studies to specifically investigate the 
independent contribution of negative symptoms to patient functioning. Previous studies have 
utilized PANSS total scores and the Schizophrenia Clinical Global Impressions-Severity and 
-Improvement scales to investigate the severity of symptoms in relation to patient outcomes 
(Bobes et al., 2010; Chue and Lalonde, 2014; Novick et al., 2007; Novick et al., 2009). In this 
study, both positive and negative persistent symptoms are clearly measured, showing the 
relative contribution of each to patient functioning. As a result, these data represent a 
valuable contribution to the field highlighting the need for future strategies for treating 
individual symptom subgroups, specifically negative symptoms, and thereby improving 
overall patient outcomes. 
 
There were some differences in patient's clinical severity and functioning across countries. 
For example, the PANSS PSFS ranged from 17 in Germany to 27 in Argentina. More striking 
is the variability in the difference between PANSS PSFS and NSFS: in Argentina and UK the 
PSFS is higher (Argentina, UK) while in France, Germany, Italy and Spain the NSFS is 
higher. However, in all cases except the UK, the CGI-SCH negative symptoms score is 
higher than the CGI-SCH positive symptoms score. Patients in the UK, Germany and 
Argentina had a higher proportion of patients with mild difficulties in the PSP. 
 
As expected, the range of therapy received varied broadly, especially between regions. 
Clozapine was the most frequently used treatment overall, although there were substantial 
differences in its prescription between countries. This variation in rate of prescription of 
clozapine between countries is consistent with previous studies, which have shown 
significant differences across countries, as well as across regions and hospitals. A 
comparison among hospitals showed that the percentages of patients who received 
clozapine varied from 5.7% to 16.8%, with a national average of 10.5% (Nielsen et al., 2012; 
Latimer et al., 2013). The causes of such varied clozapine use have not been thoroughly 
investigated (Nielsen et al., 2012), although variability in overall rates and changes in 
prescription rates over time suggest that factors other than psychopharmacological 
principles play an important role in determining the prescription of clozapine in schizophrenia 
(Xiang et al., 2011). It has been speculated that the observed differences in clozapine 
prescription may be due to varied treatment resistance within different populations or 
psychiatrists’ practice patterns, or a combination of both. Furthermore, it is likely that 
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availability of, and access to, medical resources, and cost considerations, also contributes to 
this variation.  
 
Persistence of positive and negative symptoms was associated with impaired functional 
outcomes overall, with severity of negative symptoms more likely than positive symptoms  to 
be associated with compromised patient functioning than positive symptoms (Figure 1). 
Indeed, recent evidence suggests that persistent symptoms are a stronger predictor of 
functional outcome than cognitive deficits in both chronically ill and recent-onset patients 
(Norman et al., 1999; Malla et al., 2002; Jordan et al., 2014). The evidence that symptom 
remission contributes a much larger variation in functional outcome comes from studies 
designed to include both symptoms and cognition and controlled for other potential 
predictors of functional outcome (Norman et al., 1999; Malla et al., 2002; Cassidy et al., 
2010). On the other hand evidence for cognition being a strong predictor have either not 
included symptoms or included symptoms at baseline which would obviously not show any 
role as it is residual symptoms that are important, especially negative symptoms (Cohen et 
al., 2006). Our results also replicate previous research, which demonstrated that negative 
symptoms account for much of the long-term morbidity and poor functional outcomes of 
patients with schizophrenia (Fervaha et al., 2014 (a); Buchanan, 2007). Of note, the 
relationship between PANSS score and level of functioning was stronger for negative 
symptoms compared with positive, which may emphasise the greater importance of negative 
symptoms to overall patient functioning.The results from this study therefore further 
substantiate the negative impact of persistent symptoms on the lives of patients with 
schizophrenia, endorsing the need for treatment strategies that aim to minimize both positive 
and negative symptoms, improving daily functioning and associated quality of life.  
 
A number of potential limitations of this study should be acknowledged. Only patients in the 
outpatient setting were recruited; however, patients with persistent symptoms, and often 
those with the most severe symptoms, may be living in institutions, depending on the country 
(Uggerby et al., 2011). By contrast, patients with only minimal symptoms may not visit 
outpatient clinics, making an estimate of the prevalence of persistent symptoms in the 
overall population of patients with schizophrenia difficult. Patients meeting the protocol-
defined criteria of recovery were not included in the longitudinal phase of the study, and this 
may have introduced a bias whereby such patients were under-recruited at baseline. 
However, given that the study specific determination of patients in recovery was based on a 
combination of pre-specified cut-off values on the PANSS PSFS and NSFS, and the PSP 
assessment, disease status could not have been judged conclusively prior to assessment, 
minimizing the contribution of this bias. Furthermore, the definition of recovery used may 
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have limited content validity. Whilst there is currently no consensus as to the operational 
definition of recovery in schizophrenia, the definition used is multidimensional and includes 
clinical remission and social outcomes (Emsley et al.,  2011; Andreasen et al., 2005). 
However, it does not take into account a patient’s subjective sense of recovery, quality of 
life, occupational functioning and cognitive status, which has become increasingly important 
in the recent literature (Lambert et al., 2010; Emsley et al., 2011; Leucht, 2014). Participating 
psychiatrists were provided with basic training in the use of the questionnaires; however, 
inter-rater agreement was not assessed, as the intention of Pattern was to collect real-world 
data via a non-interventional study design. Finally, since one of the inclusion criteria was that 
all patients and family members and other informal carers were required to demonstrate 
willingness to comply with the study protocol and provide informed consent the study may 
have included mostly adherent patients. 
 
5. Conclusion 
This cross-sectional study of 1379 patients, and their carers represents a valuable real-world 
contribution to the study of schizophrenia, particularly given that naturalistic data from 140 
centers across eight countries were collected. Based on this cross-sectional assessment, 
there was a high prevalence of patients with positive and/or negative persistent symptoms of 
schizophrenia and associated functional impairment. These results further substantiate the 
deleterious impact of persistent symptoms, particularly the impact of negative symptoms, on 
patients’ level of functioning. To date this non-interventional study is the largest to look at the 
severity of symptoms in schizophrenia using the PANSS Negative and Positive Symptom 
Factor scores as an independent contributing factors to the disability of schizophrenia. 
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Table 1. Assessment tools and time of data collection during the study  
(performed in parallel with routinely scheduled clinic appointments)  
  
Assessment tool Time of data collection 
Clinical rating scales 
Positive and Negative Syndrome 
Scale (PANSS) 
Baseline, 3, 6, 9, 12, 18 and 24 
months 
Clinical Global Impression-
Schizophrenia (CGI-SCH) scale 
Personal and Social Performance 
(PSP) scale 
Patient-reported outcomes 
Schizophrenia Quality Life Scale 
(SQLS) 
Baseline, 3, 6, 9, 12, 18 and 24 
months 
Short Form-36 (SF-36) Baseline, 12 and 24 months 
EuroQol-5 Dimension (EQ-5D) 
questionnaire 
Baseline and 6, 12, 18 and 24 
months 
Socio-demographics & resource use 
Client Socioeconomic and Services 
Receipt Inventory (CCSRI) 
Baseline, 3, 6, 9, 12, 18 and 24 
months 
Caregiver outcomes 
Schizophrenia Caregiver 
Questionnaire (SCQ) Baseline, 3, 6, 9, 12, 18 and 24 
months Caregiver’s Clinical Global Impression 
scale (CGI-Caregiver) 
Caregiver SF-36 Baseline, 12 and 24 months 
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Table 2. Demographic and baseline characteristics 
 
 Argentina 
(n=110) 
Brazil 
(n=100) 
Canada 
(n=117) 
France 
(n=237) 
Germany 
(n=250) 
Italy 
(n=219) 
Spain 
(n=207) 
UK 
(n=139) 
Overall 
(1379) 
Gender, n (%) 
Male 
Female 
 
68 (61.8) 
42 (38.2) 
 
71 (71.0) 
29 (29.0) 
 
93 (79.5) 
24 (20.5) 
 
174 (73.4) 
63 (26.6) 
 
160 (64.0) 
90 (36.0) 
 
159 (72.6) 
60 (27.4) 
 
140 (67.7) 
67 (32.4) 
 
108 (77.7) 
31 (22.3) 
 
973 (70.6) 
406 (7.42) 
Age, years 
Mean (SD) 
Median  
 
43.2 (13.56) 
43.0 
 
38.0 (10.54) 
37.5 
 
41.9 (12.31) 
42.0 
 
41.3 (11.30) 
40.0 
 
43.5 (11.19) 
44.0 
 
42.7 (11.04) 
43.0 
 
41.7 (10.94) 
40.0 
 
42.4 (11.56) 
41.0 
 
42.1 (11.50) 
42.0 
Race, n (%) 
White 
Black of African American 
Asian 
American Indian or Alaska Native 
Other 
Unknown  
 
108 (98.2) 
1 (0.9) 
0 
0 
0 
1 
 
74 (74.0) 
5 (5.0) 
8 (8.0) 
0 
13 (13.0) 
0 
 
89 (76.1) 
9  (7.7) 
9  (7.7) 
3  (2.6) 
4 (3.4) 
3 (2.6) 
 
Unknown* 
Unknown* 
Unknown* 
Unknown* 
Unknown* 
Unknown* 
 
120 (48.0) 
2 (0.8) 
0 
0 
1 (0.4) 
127 (50.8) 
 
217 (99.1) 
0 
1 (0.5) 
0 
0 
1 (0.5) 
 
189 (91.3) 
0 
0 
0 
2 (1.0) 
16 (7.7) 
 
125 (89.9) 
3 (2.2) 
5 (3.6) 
0 
6 (4.3) 
0 
 
937 (67.9) 
20 (1.5) 
23 (1.7) 
3 (0.2) 
26 (1.9) 
370 (26.8) 
Marital status, n (%) 
Single/unmarried 
Married/civil union 
Separated 
Divorced 
Widowed 
Non-civil union 
Not known 
 
87 (79.1) 
6 (5.5) 
5 (4.5) 
7 (6.4) 
4 (3.6) 
0 
0 
 
88 (88.0) 
4 (4.0) 
3 (3.0) 
2 (2.0) 
2 (2.0) 
0 
0 
 
85 (72.6) 
14 (12.0) 
3  (2.6) 
12 (10.3) 
1 (0.9) 
2 (1.7) 
0 
 
182 (76.8) 
29 (12.2) 
8 (3.4) 
13 (5.5) 
1 (0.4) 
2 (0.8) 
0 
 
153 (61.2) 
43 (17.2) 
5 (2.0) 
28 (11.2) 
4 (1.6) 
16 (6.4) 
1 (0.4) 
 
182 (83.1) 
19 (8.7) 
3 (1.4) 
8 (3.7) 
5 (2.3) 
0 
0 
 
173 (83.6) 
17 (8.2) 
5 (2.4) 
7 (3.4) 
3 (1.4) 
0 
0 
 
111 (79.9) 
9 (6.5) 
0 
14 (10.1) 
2 (1.4) 
3 (2.2) 
0 
 
1061 (76.9) 
141 (10.2) 
32 (2.3) 
91 (6.6) 
22 (1.6) 
23 (1.7) 
1 (0.1) 
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Living conditions, n (%) 
Living alone (+/- children) 
With spouse/partner (+/-children) 
With parents 
With other relatives 
Living with others/assisted living 
Unknown 
 
27 (24.5) 
9 (8.2) 
40 (36.4) 
12 (10.9) 
21 (19.1) 
0 
 
5 (5.0) 
4 (4.0) 
75 (75.0) 
15 (15.0) 
0 
0 
 
44 (37.6) 
14 (12.0) 
29 (24.8) 
7 (6.0) 
20 (17.1) 
3 (2.6) 
 
115 (48.5) 
35 (14.8) 
63 (26.6) 
12 (5.1) 
8 (3.4) 
2 (0.8) 
 
114 (45.6) 
59 (23.6) 
29 (11.6) 
6 (2.4) 
41 (16.4) 
1 (0.4) 
 
33 (15.1) 
21 (9.6) 
114 (52.1) 
16 (7.3) 
33 (15.1) 
0 
 
35 (16.9) 
27 (13.0) 
104 (50.2) 
13 (6.3) 
26 (12.6) 
0 
 
80 (57.6) 
14 (10.1) 
26 (18.7) 
3 (2.2) 
16 (11.5) 
0 
 
453 (32.8) 
183 (13.3) 
480 (34.8) 
84 (6.1) 
165 (12.0) 
6 (0.4) 
Main employment, n (%) 
Employed 
Voluntary/unpaid 
Sheltered employment 
Unemployed 
Student 
Housewife/husband 
Retired/pension 
Other  
 
11 (10.0) 
2 (1.8) 
2 (1.8) 
71 (64.5) 
1 (0.9) 
9 (8.2) 
5 (4.5) 
8 (7.3) 
 
5 (5.0) 
0 
1 (1.0) 
46 (46.0) 
5 (5.0) 
3 (3.0) 
21 (21.0) 
18 (18.0) 
 
18 (15.4) 
5 (4.3) 
3 (2.6) 
55 (47.0) 
2 (1.7) 
0 
7 (6.0) 
27 (23.1) 
 
35 (14.8) 
0 
11 (4.6) 
97 (40.9) 
6 (2.5) 
5 (2.1) 
18 (7.6) 
63 (26.6) 
 
40 (16.0) 
3 (1.2) 
47 (18.8) 
26 (10.4) 
10 (4.0) 
10 (4.0) 
100 (40.0) 
14 (5.6) 
 
31 (14.2) 
0 
6 (2.7) 
62 (28.3) 
9 (4.1) 
10 (4.6) 
72 (32.9) 
27 (12.3) 
 
13 (6.3) 
2 (1.0) 
9 (4.3) 
45 (21.7) 
11 (5.3) 
3 (1.4) 
58 (28.0) 
64 (30.9) 
 
8 (5.8) 
18 (12.9) 
0 
94 (67.6) 
4 (2.9) 
0 
8 (5.8) 
7 (5.0) 
 
161 (11.7) 
30 (2.2) 
79 (5.7) 
496 (36.0) 
48 (3.5) 
40 (2.9) 
289 (21.0) 
228 (16.5) 
Patients with a caregiver, n (%)  37 (33.6) 46 (46.0) 18 (15.0) 13 (5.1) 44 (15.8) 109 (49.5) 93 (44.7) 30 (21.3) 390 (27.2) 
 Concomitant medications, n (%) 
0 
1 
>1 
 
1 (0.9) 
72 (65.5) 
29 (26.4) 
 
0  
74 (74.0) 
26 (26.0) 
 
2 (1.7) 
75 (64.1) 
40 (34.2) 
 
10 (4.2) 
169 (71.3) 
58 (24.5) 
 
2 (0.8) 
165 (66.0) 
83 (33.2) 
 
1 (0.5) 
151 (68.9) 
67 (30.6) 
 
4 (1.9) 
113 (54.6) 
90 (43.5) 
 
10 (7.2) 
101 (72.7) 
28 (20.1) 
 
30   (2.2) 
920  (66.7) 
429 (31.1)           
Patient analysis set.  
SD=standard deviation.  
*Local laws prevented full collection of these data 
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Table 3. Patient assessment of disease severity based on clinical rating scales  
 
 Argentina Brazil Canada France Germany Italy Spain UK Overall 
PANSS, mean (SD) 
N 
Positive Symptom Factor Score 
Negative Symptom Factor Score 
 
109 
26.8 (5.37) 
25.1 (5.20) 
 
100 
20.7 (7.12) 
23.5 (4.90) 
 
117 
20.3 (7.03) 
20.4 (5.75) 
 
 
236 
18.4 (5.66) 
20.4 (6.38) 
 
 
249 
17.3 (7.37) 
20.8 (6.89) 
 
 
217 
23.8 (8.38) 
26.7 (8.01) 
 
 
206 
22.5 (7.66) 
24.4 (7.48) 
 
 
139 
22.9 (9.35) 
18.9 (8.62) 
 
 
1373 
21.1 (7.89) 
22.5 (7.42) 
CGI-SCH, mean (SD) 
N 
Positive symptoms 
Negative symptoms 
Depressive symptoms 
Cognitive symptoms 
Overall severity 
 
109 
3.7 (1.16) 
4.2 (0.86) 
2.6 (1.00) 
3.8 (1.08) 
4.3 (0.74) 
 
100 
3.3 (1.28) 
4.1 (0.92) 
1.9 (0.98) 
3.7 (1.09) 
4.2 (0.96) 
 
117 
3.2 (1.33) 
3.5 (0.92) 
1.8 (0.94) 
2.8 (1.07) 
3.5 (1.01) 
 
 
237 
3.3 (1.28) 
3.9 (1.15) 
2.0 (1.19) 
3.2 (1.28) 
3.8 (0.97) 
 
 
249 
2.6 (1.31) 
3.8 (1.07) 
2.5 (1.22) 
3.3 (1.09) 
3.7 (0.99) 
 
217 
3.6 (1.33) 
4.3 (1.12) 
2.9 (1.26) 
3.6 (1.15) 
4.2 (0.96) 
 
206 
3.4 (1.35) 
4.2 (1.07) 
2.6 (1.11) 
3.5 (1.07) 
4.1 (1.03) 
 
139 
3.5 (1.37) 
3.3 (1.41) 
2.4 (1.31) 
2.7 (1.28) 
3.6 (1.26) 
 
1374 
3.3 (1.35) 
3.9 (1.14) 
2.4 (1.21) 
3.3 (1.20) 
3.9 (1.03) 
PSP Scale, n (%) 
N 
Mild difficulties 
Varying degree of disability 
Patient requires intense 
support/supervision 
 
109 
18 (16.5) 
89 (81.7) 
2 (1.8) 
 
100 
6 (6.0) 
83 (83.0) 
11 (11.0) 
 
117 
8 (6.8) 
106 (90.6) 
3 (2.6) 
 
237 
27 (11.4) 
177 (74.7) 
33 (13.9) 
 
249 
45 (18.1) 
166 (66.7) 
38 (15.3) 
 
217 
20 (9.2) 
150 (69.1) 
47 (21.7) 
 
206 
17 (8.3) 
165 (80.1) 
24 (11.7) 
 
139 
40 (28.8) 
82 (59.0) 
17 (12.2) 
 
1374 
181 (13.2) 
1018 (74.1) 
175 (12.7) 
Patient analysis set.  
PSP total score-based categories: Mild difficulties: 71–100; Varying degrees of disability: 31–70; Intensive support/supervision: 0–30. 
PANSS=Positive and Negative Syndrome Scale; CGI-SCH= Clinical Global Impression-Schizophrenia Scale; PSP= Personal and Social Performance
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